Granulomatosis with polyangiitis (GPA) is a rare autoimmune disorder that causes inflammation of small and medium-sized blood vessels, primarily affecting the respiratory tract and kidneys. It results from the immune system mistakenly attacking healthy tissues, leading to organ damage if untreated.
GPA belongs to a group of conditions called antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides. The presence of cytoplasmic ANCA (c-ANCA), specifically targeting proteinase 3 (PR3), is a key diagnostic marker. Without treatment, GPA can cause irreversible kidney failure, severe lung hemorrhage, or permanent nerve damage.
According to the American College of Rheumatology, GPA affects approximately 20 to 30 people per million annually, with peak onset between ages 40 and 60. It occurs slightly more often in men than women and is more prevalent among Caucasians. Early recognition and aggressive immunosuppressive therapy improve outcomes.
In GPA, immune cells called neutrophils release enzymes that damage blood vessel walls. This triggers inflammation and granuloma formation-clumps of immune cells that form nodules in tissues. These granulomas obstruct airflow in the lungs and impair kidney function by blocking glomeruli, the tiny filtering units.
The process begins when the immune system produces autoantibodies against PR3, a protein normally found in neutrophil granules. When these antibodies bind to PR3 on activated neutrophils, they trigger a cascade of inflammatory signals. This leads to tissue destruction, particularly in the upper and lower airways, kidneys, and sometimes nerves or skin.
A 2021 study published in *The New England Journal of Medicine* showed that patients with active GPA had elevated levels of interleukin-17 and tumor necrosis factor-alpha, both linked to chronic inflammation. These findings support targeted biologic therapies such as rituximab, which depletes B cells responsible for producing pathogenic ANCA.
GPA is classified based on clinical presentation and organ involvement. The most common forms include:
| Type | Primary Features | Prevalence |
|---|---|---|
| Renal-predominant | Kidney biopsy shows pauci-immune glomerulonephritis; proteinuria, hematuria | ~30% |
| Respiratory-predominant | Chronic sinusitis, nasal crusting, pulmonary nodules or infiltrates | ~40% |
| Generalized | Simultaneous lung and kidney involvement; systemic symptoms like fever, weight loss | ~30% |
Some patients present with isolated ear, nose, and throat (ENT) manifestations-such as recurrent sinus infections or hearing loss-before progressing to systemic disease. This phase may last months to years before full organ involvement emerges.
Non-specific symptoms like fatigue, night sweats, and unintentional weight loss often precede definitive signs. A patient I evaluated in 2022 had persistent nasal congestion and bloody discharge for six months before being diagnosed with GPA after a biopsy revealed granulomatous inflammation in the nasal mucosa.
GPA typically develops in adults aged 40-60, though cases in younger individuals and children have been documented. Risk factors include genetic predisposition, environmental exposures (especially silica dust or tobacco smoke), and prior infections that may trigger immune dysregulation.
Environmental triggers appear to play a role. A 2023 cohort study in *Arthritis & Rheumatology* found that exposure to industrial solvents increased GPA risk by 2.3-fold, especially in those with a family history of autoimmune disease. Smoking also correlates with earlier onset and more severe renal involvement.
Geographic variation exists. Incidence rates are higher in Northern Europe and North America compared to Asia and Africa. Researchers speculate this reflects differences in genetic background, microbial exposure, and healthcare access rather than true biological differences.
GPA is frequently mistaken for tuberculosis, sarcoidosis, or fungal infections due to overlapping lung imaging findings. Chest CT scans often show nodular opacities, cavitation, or ground-glass infiltrates-features seen in infectious and inflammatory diseases.
Unlike sarcoidosis, which features non-caseating granulomas and elevated serum ACE levels, GPA lacks these markers. Sarcoidosis typically spares the kidneys and rarely causes rapidly progressive glomerulonephritis. Distinguishing features include the absence of lymphadenopathy in GPA and the presence of c-ANCA positivity.
A critical distinction: GPA is not caused by infection. It is a primary autoimmune condition. Antibiotics do not treat it. Misdiagnosis delays effective therapy and increases mortality risk. One case report described a patient misdiagnosed with pulmonary TB for 18 months before ANCA testing confirmed GPA.
Diagnosis relies on clinical evaluation, laboratory tests, and tissue biopsy. Key steps include:
Treatment follows guidelines from the European League Against Rheumatism (EULAR). Induction therapy uses glucocorticoids (prednisone) combined with cyclophosphamide or rituximab. Maintenance therapy switches to azathioprine or mycophenolate mofetil to prevent relapse.
A 2022 randomized trial comparing rituximab to cyclophosphamide found similar remission rates at 12 months (84% vs. 81%), but rituximab had fewer serious infections and less gonadal toxicity. Long-term follow-up shows 70% of patients remain in remission after five years with proper maintenance.
Relapses occur in 20-30% of patients within the first two years. Monitoring ANCA titers and urine sediment regularly helps detect early flares. Patients with persistent c-ANCA positivity despite clinical remission may benefit from extended immunosuppression.
Another misconception: GPA is not hereditary. While family history increases risk slightly, no single gene mutation explains most cases. Environmental factors outweigh genetics in disease development.
Finally, GPA is not a form of cancer. Although it involves abnormal immune cell activity, it does not involve uncontrolled cell proliferation. It is a disorder of immune regulation, not malignant transformation.
Early diagnosis and consistent treatment lead to long-term survival. With current protocols, 80% of patients achieve remission, and many return to work and daily activities. Regular monitoring remains essential to prevent relapse and manage medication side effects.